Home / Market News / $HCAT
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Health Catalyst Reports Financial Updates and Guidance Reduction

Nov 11, 2026, 2:14 PM UTC · Primary ticker $HCAT

Health Catalyst significantly lowered its full-year 2026 revenue guidance by 5.7% and provided a much weaker-than-expected Q3 revenue forecast. This negative revision signals ongoing operational challenges and is likely to exert further downward pressure on the company's stock.

Health Catalyst reported a significant reduction in its full-year 2026 revenue guidance, lowering the midpoint by 5.7%. Additionally, the company's Q3 revenue forecast of $55.5 million represents a substantial sequential decline from Q2's $70.49 million, indicating a worsening short-term outlook. This news is highly negative for HCAT as it suggests underlying business challenges despite meeting Q2 EPS estimates. The guidance cut implies a deterioration in future growth prospects, which will likely lead to further stock price depreciation in the short term. For traders, the key risk is continued downward momentum due to diminished investor confidence and potential analyst downgrades.

$HCAT negative Reduced revenue guidance and weak Q3 outlook
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.